Last updated: March 5, 2026
What is the Drug Associated with NDC 60429-0963?
NDC 60429-0963 refers to Everolimus, marketed under the brand name Zortress among others. It is an immunosuppressant used primarily to prevent organ rejection in transplant patients and, under different formulations, to treat specific cancers like renal cell carcinoma and neuroendocrine tumors.
Market Size and Key Drivers
The global immunosuppressant market, encompassing drugs like Everolimus, was valued at approximately USD 4.2 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 7.5% from 2023 to 2030, reaching around USD 8.5 billion by 2030[1].
Key factors influencing market growth include:
- Increasing incidence of organ transplants
- Advancements in transplant rejection management
- Expanding indications for Everolimus in oncology
- Patent expirations and biosimilar entries
Competitive Landscape
Major competitors include:
- Sirolimus (Rapamune)
- Tacrolimus (Prograf)
- Everolimus (Zortress, Afinitor)
- Biosimilars entering the market
Pharmaceutical companies such as Novartis, Pfizer, and Sandoz are active in the space, with biosimilars offering potential price reductions.
Regulatory and Patent Status
Everolimus's primary patent expired in the U.S. in 2017, with patent protections in other regions varying[2]. This expiration has prompted biosimilar development, which may influence pricing and market dynamics.
Price Trends and Projections
Current Pricing (2023)
- Brand-name Everolimus (Zortress): Wholesale acquisition cost (WAC) ranges from USD 2,500 to USD 3,000 per month for a typical transplant dose.
- Biosimilars and Generics: Priced approximately 30-50% lower than brand-name counterparts, with monthly costs around USD 1,500 to USD 2,000.
Price Trajectory (2023-2030)
| Year |
Estimated Brand Price (USD/month) |
Estimated Biosimilar Price (USD/month) |
Market Share of Biosimilars (%) |
| 2023 |
2,750 |
1,750 |
10 |
| 2025 |
2,600 |
1,500 |
25 |
| 2027 |
2,400 |
1,300 |
45 |
| 2030 |
2,200 |
1,100 |
60 |
Biosimilar price reductions are expected to accelerate market penetration, with median prices decreasing by approximately 20-25% by 2027[3].
Factors Influencing Price Changes
- Biosimilar approvals and market entry
- Healthcare policy shifts favoring cost containment
- Patent litigation and legal challenges
- Adoption rates in transplant and oncology indications
Regulatory Impact on Market and Prices
Regulatory agencies such as the FDA and EMA continue to facilitate biosimilar approvals, with Everolimus biosimilars already approved in multiple jurisdictions. Such approvals are generally associated with increased competition and lower prices[4].
Conclusion
The market for Everolimus (NDC 60429-0963) is characterized by a mature landscape with increasing biosimilar competition. Prices are expected to decline progressively, especially after 2025, as biosimilars gain larger market shares. The total market size will expand driven by the growing number of transplant procedures and oncology treatments.
Key Takeaways
- The global immunosuppressant market is projected to reach USD 8.5 billion by 2030.
- Brand-name Everolimus prices currently range USD 2,500–3,000/month.
- Biosimilar entry is expected to reduce prices by 20-25% by 2027.
- Market share of biosimilars is expected to grow from 10% in 2023 to 60% by 2030.
- Patent expirations and regulatory approvals will continue to drive price declines.
FAQs
1. How does biosimilar entry affect Everolimus pricing?
Biosimilar entry typically reduces prices by 30-50%, increasing market competition and leading to overall lower costs.
2. What are the primary indications for Everolimus?
It is indicated for preventing organ rejection in transplant patients and treating certain cancers, including renal cell carcinoma.
3. Are there significant differences between Everolimus and its biosimilars?
Biosimilars are highly similar but not identical; regulatory agencies require rigorous comparability, ensuring no meaningful clinical differences.
4. How will patent expirations influence market competition?
Patent expirations, notably in 2017 in the U.S., enable biosimilar development and approval, increasing competition and reducing prices.
5. What regions dominate the market for Everolimus?
North America and Europe lead in market size, driven by high transplant and oncology treatment rates, with emerging markets expanding rapidly.
References
[1] Grand View Research. (2023). Immunosuppressant Drugs Market Size, Share & Trends.
[2] US Patent Office. (2017). Patent expiration data for Everolimus.
[3] IQVIA. (2023). Biosimilar market penetration projections.
[4] FDA. (2021). Biosimilar approval pathways and recent approvals.
